Trastuzumab Deruxtecan Provides Long-Term Survival Benefit for HER2+ Metastatic Breast Cancer
Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) continued to show clinically meaningful efficacy improvements and manageable toxicities compared with treatment of physician’s choice (TPC) in patients with HER2-positive metastatic breast cancer who …